Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents

Date
2018
Author
Ozguroglu, Mustafa
DELANOY, Nicolas
BELLMUNT, Joaquim
OUDARD, Stephane
ANGELERGUES, Antoine
EFSTATHIOU, Eleni
GYFTAKI, Revekka
WYSOCKI, Piotr Jan
LAINEZ, Nuria
GONZALEZ, Iria
CASTELLANO, Daniel E.
GARCIA CARBONERO, Iciar
FLECHON, Aude
BORREGA, Pablo
GUILLOT, Aline
CAMPOS BALEA, Begona
LE MOULEC, Sylvestre
ESTEBAN, Emilio
MUNARRIZ, Javier
RUBIO, Gustavo
BIRTLE, Alison J.
Metadata
Show full item record
Abstract
Several agents have demonstrated an overall survival (OS) benefit in metastatic castration-resistant prostate cancer (mCRPC); however, optimal sequencing is unknown. Retrospective analysis of data from 574 mCRPC patients showed increasing OS with the number of therapies provided; a sequence including docetaxel, cabazitaxel (CABA), and an androgen receptor-targeted agent (ART) provided the greatest benefit. Prior administration of ART did not appear to influence CABA activity. These findings will help guide treatment decisions in daily practice.
URI
http://hdl.handle.net/20.500.12627/14029
https://doi.org/10.1016/j.clgc.2018.02.016
Collections